Wegovy Perks Sustained for Years; Most Have 'CKM Syndrome'; New Adrenal Guidelines

— News and commentary from the endocrinology world

by Kristen Monaco, Senior Staff Writer, �鶹��ý May 14, 2024

Endo Break over a computer rendering of a man with illustrated body organs.

One in eight U.S. adults (Ozempic, Wegovy) or another GLP-1 agonist, a KFF poll found.

Metabolic benefits of , according to findings presented at the European Congress on Obesity. In people with overweight or obesity without diabetes, semaglutide yielded an average 10.2% weight loss and 7.7 cm reduction in waist circumference after 4 years. (Nature Medicine)

Nearly 90% of U.S. adults 20 and older met any level criteria for "CKM syndrome" -- a combination of -- and 15% met criteria for advanced stages. (JAMA)

Around 25% of people 16 or older with insulin-dependent diabetes had , according to a meta-analysis of 45 studies. (Eating Behaviors)

The Endocrine Society and European Society of Endocrinology released new joint guidelines on . (Journal of Clinical Endocrinology & Metabolism)

An Australian study found people who were dispensed a GLP-1 receptor agonist were 44% more likely to . (Diabetes, Obesity and Metabolism)

Some women on GLP-1 receptor agonists are becoming pregnant . (CNN)

Hilary Cass, OBE, who published a report that led to restrictions on in Britain, said U.S. doctors are "out of date" on youth gender medicine. (New York Times)

Premature menopause was in research presented at the annual European Congress of Endocrinology. (Newsweek)

Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.